PMID- 27536069
OWN - NLM
STAT- MEDLINE
DCOM- 20170410
LR  - 20181113
IS  - 1177-8881 (Electronic)
IS  - 1177-8881 (Linking)
VI  - 10
DP  - 2016
TI  - Metformin increases pressure pain threshold in lean women with polycystic ovary 
      syndrome.
PG  - 2483-90
LID - 10.2147/DDDT.S109086 [doi]
AB  - BACKGROUND: Despite the strong preclinical rationale, there are only very few 
      data considering the utility of metformin as a potential pain therapeutic in 
      humans. The aim of this study was to determine the association between metformin 
      therapy and pressure pain threshold (PPT) in lean women with polycystic ovary 
      syndrome (PCOS). We hypothesized that metformin therapy in lean PCOS women 
      increases PPT. MATERIALS AND METHODS: Twenty-seven lean PCOS women with free 
      androgen index phenotype >5 and 18 lean healthy controls were enrolled in the 
      study. Fifteen of the PCOS women were randomly assigned to be treated with 
      metformin 1,500 mg daily for 6 months. PPT and plasma beta-endorphin levels were 
      measured in all women at the beginning of the study and after 6 months of 
      observation. RESULTS: We observed an increase in PPT values measured on deltoid 
      and trapezius muscle in the PCOS with metformin group after 6 months of metformin 
      administration (4.81+/-0.88 kg/cm(2), P<0.001 on deltoid muscle, and 5.71+/-1.16 
      kg/cm(2) on trapezius muscle). We did not observe any significant changes in PPT 
      values in the PCOS without treatment group and in controls. We did not observe 
      any significant changes in serum beta-endorphin levels in any studied groups during 
      the 6-month observation. CONCLUSION: We conclude that metformin therapy increases 
      PPT in lean PCOS women, without affecting plasma beta-endorphin concentration. Our 
      results may suggest the potential role of metformin in pain therapy. We propose 
      that larger, randomized studies on metformin impact on pain perception should be 
      performed.
FAU - Kialka, Marta
AU  - Kialka M
AD  - Department of Gynecological Endocrinology, Jagiellonian University, Medical 
      College, Krakow, Poland.
FAU - Milewicz, Tomasz
AU  - Milewicz T
AD  - Department of Gynecological Endocrinology, Jagiellonian University, Medical 
      College, Krakow, Poland.
FAU - Sztefko, Krystyna
AU  - Sztefko K
AD  - Department of Clinical Biochemistry, Jagiellonian University, Medical College, 
      Krakow, Poland.
FAU - Rogatko, Iwona
AU  - Rogatko I
AD  - Department of Clinical Biochemistry, Jagiellonian University, Medical College, 
      Krakow, Poland.
FAU - Majewska, Renata
AU  - Majewska R
AD  - Department of Epidemiology, Chair of Epidemiology and Preventive Medicine, 
      Jagiellonian University Medical College, Krakow, Poland.
LA  - eng
PT  - Journal Article
DEP - 20160803
PL  - New Zealand
TA  - Drug Des Devel Ther
JT  - Drug design, development and therapy
JID - 101475745
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Female
MH  - Humans
MH  - Metformin/pharmacology/*therapeutic use
MH  - Pain Threshold
MH  - Polycystic Ovary Syndrome/*drug therapy
PMC - PMC4977100
OTO - NOTNLM
OT  - metformin
OT  - pain therapy
OT  - polycystic ovary syndrome
OT  - pressure algometry
OT  - pressure pain threshold
EDAT- 2016/08/19 06:00
MHDA- 2017/04/11 06:00
PMCR- 2016/08/03
CRDT- 2016/08/19 06:00
PHST- 2016/08/19 06:00 [entrez]
PHST- 2016/08/19 06:00 [pubmed]
PHST- 2017/04/11 06:00 [medline]
PHST- 2016/08/03 00:00 [pmc-release]
AID - dddt-10-2483 [pii]
AID - 10.2147/DDDT.S109086 [doi]
PST - epublish
SO  - Drug Des Devel Ther. 2016 Aug 3;10:2483-90. doi: 10.2147/DDDT.S109086. 
      eCollection 2016.